Related Experiment Video
Updated: Apr 23, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Histopathological evidence of Fabry disease in a female patient with left ventricular noncompaction
Elisabete Martins1, Teresa Pinho2, Stirling Carpenter3
1Medical School of Porto, Department of Medicine, São João University Hospital, Porto, Portugal.
Insights
Fabry disease, a genetic disorder, can present atypically in women. This case highlights left ventricular noncompaction as a potential sign, emphasizing the need for broader diagnostic considerations.
Area of Science:
- Genetics
- Cardiology
- Rare Diseases
Background:
- Fabry disease is an X-linked lysosomal storage disorder due to alpha-galactosidase gene mutations.
- Cardiac involvement, typically left ventricular hypertrophy, is common, but data on LV noncompaction are limited.
- Cardiac complications are a leading cause of mortality in females with Fabry disease.
Observation:
- A 30-year-old asymptomatic woman, heterozygous for a nonsense alpha-galactosidase mutation (p.R220X), was diagnosed with left ventricular (LV) noncompaction via cardiac MRI.
- She did not exhibit LV wall hypertrophy, an atypical presentation.
- Endomyocardial biopsy revealed glycosphingolipid deposition in cardiomyocytes, confirming Fabry cardiomyopathy.
Findings:
- This case demonstrates LV noncompaction in a heterozygous female with Fabry disease without typical hypertrophy.
- Histopathology confirmed Fabry cardiomyopathy through glycosphingolipid deposition.
- Enzyme replacement therapy was recommended for the patient.
Implications:
- Endomyocardial biopsy is crucial for diagnosing atypical cardiac Fabry disease, even in heterozygous women.
- Fabry disease should be considered in the differential diagnosis of left ventricular hypertrabeculation/noncompaction.
- This finding expands the understanding of cardiac manifestations in female Fabry disease patients.
Abstract:
Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the alpha-galactosidase gene. The most frequent cardiac presentation of Fabry disease is cardiomyopathy characterized by left ventricular (LV) hypertrophy, usually concentric. Heart disease in affected females tends to be clinically recognized later than in males and cardiac complications are the most frequently reported cause of death in females with Fabry disease. There are few data regarding the association between Fabry disease and LV noncompaction. We report a case of a 30-year-old asymptomatic woman, heterozygous for a nonsense alpha-galactosidase gene mutation (p.R220X), who presented LV noncompaction on cardiac magnetic resonance imaging, without LV wall hypertrophy. Histopathological examination of myocardial fragments showed marked deposition of glycosphingolipids in cardiomyocytes, confirming the diagnosis of Fabry cardiomyopathy. Based on this finding, the patient was proposed for enzyme replacement therapy. This case illustrates the role of endomyocardial biopsy in the clarification of doubtful or atypical findings related to cardiac Fabry disease, even in heterozygous women, and corroborates the contention that Fabry disease should be included in the differential diagnosis of LV hypertrabeculation/noncompaction.
More Related Videos
07:09A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mitral Stenosis II: Clinical features and Diagnostic Tests
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy